- Alzamend Neuro Inc ALZN contracted Altasciences to conduct a six-month Phase 1 comparative bioavailability study for AL001 for dementia related to Alzheimer's disease in September 2021.
- AL001 is a lithium-delivering ionic cocrystal under development as an oral treatment.
- The Phase 1 study will investigate the pharmacokinetics of lithium following a single dose of AL001 compared to a typical single dose of a marketed 300 mg immediate-release lithium carbonate capsule in healthy subjects.
- The lithium and salicylate components of AL001 will be given within the amounts already approved for use in patients.
- Related: Alzamend Neuro's Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models.
- Price Action: ALZN shares are down 4.77% at $3.33 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralalzheimer's treatmentBriefsPhase 1 Trial
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
